Study of Arimoclomol in Inclusion Body Myositis (IBM)

PHASE2CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

August 16, 2017

Primary Completion Date

January 11, 2021

Study Completion Date

January 11, 2021

Conditions
Inclusion Body Myositis
Interventions
DRUG

Arimoclomol

2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime

OTHER

Placebo

2 matched placebo capsules taken 3 times daily during breakfast, early afternoon, and at bedtime

Trial Locations (12)

14642

University of Rochester, Rochester

21218

Johns Hopkins University, Baltimore

22908

University of Virginia, Charlottesville

43221

The Ohio State University, Columbus

66160

University of Kansas Medical Center, Kansas City

77030

Nerve and Muscle Center of Texas, Houston

80045

University of Colorado School of Medicine, Aurora

84112

University of Utah, Salt Lake City

85018

Phoenix Neurological Associates, Phoenix

92697

University of California, Irvine, Irvine

02115

Brigham and Women's Hospital, Boston

WC1N 3BG

University College of London, London

All Listed Sponsors
collaborator

University of Kansas Medical Center

OTHER

collaborator

University College, London

OTHER

lead

ZevraDenmark

INDUSTRY

NCT02753530 - Study of Arimoclomol in Inclusion Body Myositis (IBM) | Biotech Hunter | Biotech Hunter